SCHEMBL14656703

SCHEMBL14656703

COc1ccc2c(c1)ncn2-c1ccc(NC=O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 4/20 0.64
▸ HPGD P15428 6/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ ALDH1A1 P00352 7/20 0.57
▸ MAPT P10636 6/20 0.57
▸ HTT P42858 4/20 0.56
▸ LMNA P02545 2/20 0.56
▸ L3MBTL1 Q9Y468 2/20 0.56
▸ GAA P10253 2/20 0.55
▸ ALOX12 P18054 1/20 0.55
▸ KDR P35968 1/20 0.52
▸ GSK3B P49841 1/20 0.52
▸ KDM4E B2RXH2 2/20 0.52
▸ NPC1 O15118 2/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ MAPK1 P28482 1/20 0.50
▸ MAPK10 P53779 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20627764 0.85 FGFR1 (0.49) FGFR1HPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL20627045 0.85 FGFR1 (0.49) FGFR1HPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL25487479 0.84 SMN1; SMN2 (0.47) FGFR1HPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL19350865 0.83 FGFR1 (0.55) FGFR1HPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL20627475 0.81 NPC1 (0.47) FGFR1HPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL29505576 0.81 SMN1; SMN2 (0.65) FGFR1HPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL4590705 0.79 FGFR1 (0.74) FGFR1HPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL29357610 0.79 FGFR1 (1.00) FGFR1HPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL7989819 0.79 FGFR1 (1.00) FGFR1HPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL20627049 0.79 AURKA (0.50) FGFR1HPGDSMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017152874-A1 UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 恩瑞生物医药科技(上海)有限公司 2017-09-14 — — WO disclosed
EP-2565185-A1 [5,6]HETEROCYCLIC COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-03-06 — — EP disclosed
US-20130029964-A1 [5, 6] HETEROCYCLIC COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-31 — — US disclosed
US-20130029964-A1 [5, 6] HETEROCYCLIC COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-31 — — US disclosed
US-20130029964-A1 [5, 6] HETEROCYCLIC COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029964-A1 [5, 6] HETEROCYCLIC COMPOUND BMP2, BMP4, SOST FGFR1 128/4885HPGD 1022/4885SMN1; SMN2 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback